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1. Introduction
Positron  Emission  Tomography  (PET),  particularly  with  18-Fluorodeoxyglucose  (FDG),
continues to define and expand its role in oncologic management. Beyond tumor size, as
definable by computed tomography (CT), PET provides a measure of metabolic activity in
tumors  and  is  integral  in  initial  workup for  multiple  disease  sites  including  head/neck
squamous  cell  carcinoma,  non-small  cell  lung  cancer  (NSCLC),  lymphoma,  and  many
others. For head and neck cancers, FDG PET imaging facilitates early detection of persis‐
tent and recurrent head/neck squamous cell  carcinoma after chemoradiotherapy, increas‐
ing deferral of surgical neck dissection to the salvage setting in many cases. In the setting
of non-small-cell lung cancer, PET is further considered standard of care for radiotherapy
treatment  planning.  Post-treatment  PET  has  further  shown  to  facilitate  assessment  of
treatment response, with metabolic response seen on PET pre-dating CT-based radiograph‐
ic response. Though routine post-therapy PET after definitive non-surgical management is
standard management for head/neck squamous cell carcinomas, evidence to support this
routine use for other subsites is lacking and thus currently not recommended for various
organ sites including lung. This chapter herein discusses various PET imaging techniques
and assessment  variables  that  have  been  used  to  investigate  assessment  of  response  to
oncologic treatment. In particular, assessment of response with early and late post-radiother‐
apy  PET  imaging  for  head  and  neck,  NSCLC,  rectal  cancer,  esophageal  cancer,  and
lymphoma are discussed. Recent research involving on-treatment PET imaging as well as
future work are further presented.
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2. PET technique
2.1. 18F-FDG
PET is a medical imaging technique employing the unique parameters of decay of positron-
emitting isotopes. Today, PET is routinely used in conjunction with computed tomography
(CT) in a combined medical imaging device, PET-CT, allowing anatomic image correlation
with the functional imaging obtained by PET.
A number of PET radiotacers have been used in oncology, though 18F-Flourodeoxyglucose
(FDG) is FDA-approved and most commonly employed. Other agents including 18F-FMISO
(18F-Fluoromisonidazole), 18FLT (18F-Fluorothymidine), 16b-18F-Fluoro-5a-Dihydrotestoster‐
one (18F-FDHT), 60Cu-ATSM (Copper-diacetyl-bis(N4-methylthiosemicarbazone)), 18F-FES
(16a-18F-fluoro-17b-estradiol), 11C-MET (11C-methionine), show significant potential to
monitor the response to therapy before, during, or after therapeutic intervention[1].
18F-FDG chemically is 2-deoxy-2-18F-fluoro-D-glucose, a glucose analog. On 18FDG, the
positron-emitting radioactive isotope fluorine-18 is substituted at the 2' position of the glucose
molecule preventing glycolysis, which requires a hydroxyl group at the 2’ position. It has
significantly increased uptake in tissues with increased metabolic activity, in particular, most
malignancies [2]. With increased demand for gluose, tumors tend to have increased expression
of glucose transport proteins at the cellular membrane as well as increased hexokinase [3].
With its relatively short half-life of 110 minutes, in tissues with rapid uptake, the 18F decay
occurs primarily when trapped intracellularly, helping visualize these areas on PET. Malig‐
nancies with moderate to high 18F-FDG uptake include most lung cancers, colorectal cancers,
esophageal cancers, gastric cancers, head and neck cancers, cervical cancers, ovarian cancers,
breast cancers, lymphomas, and melanoma [4]. Hepatocellucar carcinoma, testicular cancers,
renal cancers, sarcomas, and neuroendocrine tumors have variable 18F-FDG uptake [4].
Prostate adenocarcinoma, the most common cancer in males, has generally low metabolic
activity, rendering 18F-FDG particularly less helpful for this malignancy in the primary setting,
leading to potential false negative interpretation [5–7]. As 18F-FDG undergoes physiologic
excretion through the bladder hinders evaluation of both bladder and prostate malignancies.
Overall, 18F-FDG has been the most used oncologic tracer, but its applicability is not universal
across all malignancies, nor is its uptake specific to only neoplasm. Though aberrant tumor
growth in malignancy routinely results in increased 18F-FDG avidity, it is not tumor specific
other benign tissue and benign conditions can also have variable uptake of 18F-FDG (e.g.
inflammation or hyperplastic bone marrow) potentially leading to false positive findings [4,7].
As bone marrow hyperplasia and inflammation are not uncommon consequences after
oncologic treatment including surgery, radiation therapy, and/or chemotherapy, 18F-FDG PET
has limitations particulary in post-therapeutic assessment.
2.2. Other radiotracers
Beyond 18F-FDG, other markers exploit other cellular mechanisms for biologic imaging with
PET. Other markers have been used to assess tumor proliferation with markers of DNA
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synthesis. As thymidine is unique to DNA, this has been exploited with various radiotracers
including 11C-thymidine—which is limited by the short half-life of 11C—as well as thymidine
analogs 18F-FLT and 8F-FMAU with the longer half-life of 18F [8]. 18F-FLT acts as a substrate of
cytosolic thymidine kinase 1 (TK1), a key enzyme for salvage DNA synthesis, and 8F-FMAU
is a substrate of thymidine kinase 2 (TK2), located in mitochondria, resulting in different
distributions of these markers in tissue [9,10]. Although tumors tend to be less avid of 18F-FLT
in comparison go 18F-FDG, tumor delineation from background tissue can be superior with
18F-FLT in regions such as the brain, mediastinum, and intestines, where normal physiologic
uptake of 18F-FLT in these areas are much lower, yielding a high tumor-to-background ratio
[1,11–13]. In a head-to-head comparison of 18F-FLT to 18F-FDG to assess chemotherapy response
in patients with breast cancer who had imaging with both radiotracers, change in FLT uptake
after one cycle of chemotherapy better predicted late changes in tumor marker levels and
correlated well with eventual radiographic tumor response [14]. Though less employed in
comparison to 18F-FLT, 18F-FMAU has shown ability to visualize breast, brain, lung, and
prostate tumors. As 18F-FMAU shows low uptake in normal bone marrow—as opposed to 18F-
FLT, which has high bone marrow uptake—18F-FMAU is more suitable for visualization of
metastatic prostate cancer.
Radiolabeled Cu-ATSM (60/62/64Cu-ATSM) and 18F-FMISO are currently the two primary
radiotracers employed for imaging tissue hypoxia—correlated with decreased sensitivity to
treatment—and has been with worse clinical outcomes [15,16]. 60Cu-ATSM has been found to
predict aresponse to therapy for NSCLC and predict both recurrence and survival outcomes
for cervical and rectal cancers [17–19]. Clinically, pretreatment 18F-FMISO has been shown to
predict survival in patients with head and neck cancer and glioblastoma multiforme [20,21].
Various amino acid radiotracers have been used, with 11C-MET (a methionine analog) the most
common. It has found a niche in CNS malignancies. In malignant gliomas, decreased uptake
during temozolomide therapy has shown improved time to progression; areas of uptake have
shown areas at high risk of recurrence, and has helped distinguish post-radiation necrosis
versus recurrent malignancy [22–24].
An additional class of radiotracers have aimed to assess hormone receptors, as receptors play
an integral role in malignancies, paticulary prostate and breast cancers. 18F-FES is the most
commonly used, showing correlation with estrogen receptor (ER) levels as well as response to
aromatase inhibitors [25,26]. Ultimately, pretreatment uptake values have shown to predict
patients who would or would not respond to therapy [25]. For prostate cancer, 18F-FDHT is an
analog of 5α-dihydrotestosterone. Correlation with treatment response has not as well been
shown in prostate cancer with this marker, though 18F-FDHT uptake has been associated with
high PSA levels [27].
Single-phase / Dual-phase / Dynamic PET
Historically, PET imaging was obtained with a single static set of images obtained up to 1 hour
after injection of 18F-FDG. As noted previously, a diagnostic limitation of PET imaging for
oncologic diagnosis are the false positive findings secondary to inflammation quite commonly
associated to therapeutic response. As 18F-FDG uptake and retention kinetics are potentially
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different between tumor and normal tissue inflammation, people have investigated more
dynamic methods of acquiring metabolic PET data.
In a series of 21 patients with head and neck carcinomas, dual-time-point 18F-FDG PET studies
helped differentiate malignancy from inflammation [28]. Standard uptake values (SUVs) of
tumors were shown to increase on the second (delayed) study by mean of 12% in comparison
to matched contralateral normal tissue which showed a mean decrease of 5% on delayed
imaging (p<0.05) [28]. Inflammatory sites showed relatively stable uptake over the two scans;
time interval between scans correlate with tumor SUV increase; and interval of greater than
30 minutes was recommended for separation [28].
For evaluation of pulmonary nodules, an early study of 36 patients siwht 38 pulmonary
nodules, malignant or benign, underwent dual-time-point PET at 70 and 123 minutes post-
injection [29]. A similar trend was seen with mean increase of tumor SUV of 20% (from 3.7 to
4.4) in malignant lesions from early to delayed scan (P<0.01); benign lesions showed stable and
lower mean SUVs (1.1 on both early and delayed imaging) [29]. They determine a threshold
of 10% increase from early to delayed imaging as the best predictor, reaching sensitivity of
100% and specificity of 89% [29]. Other data have shown similar trends of increased 18F-FDG
uptake from first to second scan in malignant tissue and stable to decreased uptake in benign
lesions [30].
In a study of 47 patients with suspected pancreatic cancer, patients had dual-time-point 18F-
FDG PET imaging acquired 1 and 2 hours after injection; further, some patients had a third
scan at the 3-hour time point after injection [31]. Twenty-two lesions were malignant, whereas
20 were benign. With a constant SUV threshold, the initial 1-hour PET was found to be 95%
sensitive, missing one of 22 malignant lesions, and 83% accurate. With addition information
of 2-hour PET imaging, retention characteristics of 18F-FDG increased diagnostic accuracy to
91.5%, with no decrease in false negatives [31]. The additional information provided by a 3-
hour PET did not improve diagnostic accuracy beyond the dual-phase imaging obtained at
the 1-hour and 2-hour time points [31].
With  these  potential  diagnostic  advantages  from dual-phase  PET-CT (with  2  PET scans
separated by a time interval) has grown increasingly common. With the extra information
provided  with  dual-phase  imaging,  people  have  further  investigated  ‘dynamic  PET’
imaging, obtaining continuous PET data over time rather than at discrete or brief time spans,
adding  further  breadth  of  data  to  kinetic  profiles  of  uptake.  Early  work  used  dynamic
continuous imaging to model discrete time-point imaging, showing linear change over time
in  patients  with  breast  cancer.  A  recent  study  utilized  dynamic  PET imaging  with  18F-
FCho (18F-labelled fluoromethylcholine) to assess time-activity curves of space occupying
brain lesions [32]. Another recent study used a dynamic PET-CT approach to assess cervical
adenopathy in patients with oral/head and neck cancer; consecutive imaging at nine time
points  with  PET/CT  were  obtained  from  60-115  minutes  after  injection  [33].  At  our
institution, we have recently initiated an adaptive radiation therapy protocol for patients
with  head/neck  cancer  in  which  patients  receive  weekly  dynamic  PET  imaging  over
approximately 90 minutes during the course of treatment.
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Though PET imaging acquires three-dimensional (3D) data, as CT technology has advanced
to enable four-dimensional (4D) imaging with full 3D CT image sets corresponding to various
portions of a respiratory cycle, so now have 4D-PET-CTs come into clinical use, with potential
to reduce image smearing, improve accuracy of PET-CT co-registration, and increase the
measured SUV [34,35]. A study evaluating 57 pulmonary lesions showed particular benefit in
characterizing smaller tumors, with 4D studies showing higher differences in SUVmax percent
difference in comparison to 3D studies (p<0.05) assessment of smaller lesion lung lesions, with
better characterization [36]. A recent study illustrated utility of respiratory-correlated 4D-PET-
CT for target delineation of squamous cell carcinoma of the esophagus, further indicating SUV
threshold of 20% or 2.5 for autocontouring the gross tumor volume (GTV) [37]. Algorithms for
semiautomatic contouring have also been proposed for pulmonary lesions with minimal
difference (0.1 ± 0.1 mm) on phantom studies and 0.8 ± 0.2 mm on patient tumors [38]. Four-
dimensional PET/CT has been reported to facilitate planning stereotactic radiotherapy of liver
metastases [39] and pulmonary tumors [40].
3. PET parameters
From an oncologic standpoint, PET imaging is notably quite useful in its ability to quantitate
parameters associated with PET uptake. An assortment of quantitative values can be obtained
from each scan and from multiple-time-point scans, as well as across different scans obtained
at different time points with respect to treatment (e.g. pre-treatment versus post-treatment),
providing valuable information for treating physicians.
A common measurement of PET images for clinicians is the semi-quantitative value referred
to as “standardized uptake value (SUV) [41].” Standardized uptake values are calculated
throughout the three-dimensional array of CT regions, with variable SUVs throughout an
image. SUV provides an index of regional tracer uptake and is a function of local radioactivity
concentration, injected activity, and patient’s weight. 18F-FDG SUV can help differentiate
tumor from tissue, and when used, corrections to calculation are recommended [42]. A
common method of correction accounts for a patient’s lean body mass “SUVlbm,” commonly
written as “SUVlbw” (lbw=“lean body weight”), “SUVlean,” or “SUL.”[43]
( / )
( ) / ( )
ilean
i
Radioactivity C mLSUV Dose mC leanbody mass kg
m= (1)
lean lbm lbwSUV SUV SUV SUL= = = (2)
Within a region of interest (ROI) on a PET-CT, various PET quantitative factors can readily
be  obtained.  The  most  commonly  reported  value  from  PET-CT  oncologic  imaging  the
maximum SUV value (SUVmax). SUVmax values are measured and reported at areas concern‐
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ing for malignancy (e.g. a primary tumor and associated regional lymph nodes and distant
metastases as well as other highly avid areas that may represent inflammation or reactive
changes). Pre-treatment SUVmax with 18F-FDG has been reported to be prognostic for many
organ sites including lung [44–46],  head and neck [47],  esophagus [48,49],  gastroesopha‐
geal junction [49] gastric [50], pancreas [51] cervix [52], rectum [53,54], lymphoma [55], and
soft tissue sarcoma [56].
Beyond SUVmax of an ROI, the arithmetic mean SUV (SUVmean) of voxels within the ROI have
been used for oncologic assessment [57–59]. New parameters, which show promise in
oncologic assessment, include the metabolic tumor volume (MTV) and total glycolytic activity
(TGA) [60–63]. The MTV is defined as the tumor volume based on PET uptake and can be
particularly helpful in comparison to CT-imaging when background density is similar to
tumor density on CT. The boundary of MTV can be defined manually or with various
parameters such as a fixed SUV threshold, percentage of SUVmax (e.g. 38%, 50%, and 60%), and
gradient. On pre-treatment imaging prior to radiotherapy the volume delineated by PET-
fusion to planning CT effectively corresponds to the MTV, which is utilized for biologically-
targeted radiotherapy [64–66]. Such methods have been used extensively for lung radiotherapy
planning, where PET staging is recommended [67]. MTV has shown to predict overall survival
in lung cancer [61], head and neck cancer [60], and esophageal cancer [68].
Total glycolytic activity (TGA), defined as the (MTV) x (SUVmean), is the primary PET parameter
that includes both both anatomic (size) as well as metabolic parameters (e.g. with 18F-FDG). In
an analysis of TGA and MTV in 45 patients with oral or oropharyngeal SCC, stage, on
univariate cox regression, MTV and TGA were the most associated with progression-free
survival (PFS) and overall survival (OS) (p=0.002 and p=0.006, respectively), moreso than
tumor grade (p=004) and SUVmax (p=0.56) [69].
TGA MTV x SUVmean= (3)
Retention index (RI) is a dynamic parameter that can be calculated with dual-time-point (early
and delayed) PET imaging, where RI is the difference of SUVmax on two scans divided by
initial SUVmax. Rate of decline of RI during lung irradiation has shown to predict locoregional
recurrence [70]. Further, in an analysis of 68 women with breast cancer, in comparison to other
parameters including early and delayed SUVmax, RI showed best relation to biologic parameters
including grade, Ki-67, and c-erbB-2 expression [71].
max max
max
delayed early
early
SUV SUVRI SUV
-= (4)
From an oncologic standpoint, beyond the importance of baseline PET imaging for staging
and radiotherapy planning, subsequent PET scans, whether during treatment or subsequent,
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are used for assessment of treatment response. From such data, inter-PET analysis can be
performed (e.g. comparison of a pre-treatment scan to a post-treatment scan), not to be
confused with factors such as the RI which are measured across two different scans performed
during two time points of a single PET (e.g. early and delayed scans). Inter-PET parameters
include the difference or change in (delta, Δ) values of parameters already previously dis‐
cussed as well as “percent of” (e.g. percent of baseline), percent reduction from baseline, and
rate of change (velocity “VEL”). Examples of such variables comparing a new PET to a baseline
PET are as indicated below, where t is the time between PETs..
max max maxnew baselineSUV SUV SUVD = - (5)
%
maxmax 100max
newBaseline
baseline
SUVSUV xSUV= (6)
% %max 100% maxreduction baselineSUV SUV= - (7)
max
max maxnew baselineSUV SUV SUVVEl t
-= (8)
4. Response criteria
Various methods for assessing and categorizing response of tumors based on radiographic
imaging have been proposed, including the World Health Organization (WHO) criteria, the
Response Evaluation Criteria in Solid Tumors (RECIST), and RECIST 1.1 [72–75]. Such
criterica, depend on radiographic imaging, which may not best assess the biologic response,
particularly given that metabolic response on PET routinely anatomic radiographic response
on CT [76]. Accordingly, methods of categorizing response with PET have been developed,
namely the European Organization for Research and Treatment of Cancer (EORTC) criteria
and newer PET Response Criteria in Solid Tumors (PERCIST, version 1.0) [43,77]. A separate
metric of response definitions using 18F-FDG PET has been developed for lymphoma response
and used for clinical trials [78]. Definitions of criteria are delineated in Table 1, Table 2, Table
3, Table 4, and Table 5.
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RECIST 1.1 (2009) [75]
(Anatomic)
EORTC (1990) [77]
(Metabolic)
PERCIST (2009) [43]
(Metabolic)
Measurable lesions have
minimum size of 10 mm by CT
scan,10 mm caliper
measurement by clinical exam
(lesions which cannot be
accurately measured with
calipers should be recorded as
non-measurable), or 20 mm by
chest X-ray. All other lesions are
considered non-measurable
Tumor regions defined on pretreatment
scan should be drawn on region of high
18F-FDG uptake representing viable
tumor. Whole tumor uptake should also
be recorded.
Uptake measurements should be made
for mean and maximal tumor ROI
counts per pixel per second calibrated
as MBq/L.
Partial volume may affect measurement
of 18F-FDG uptake.
Tumor size from anatomic imaging in
relation to PET scanner resolution
should be documented where possible.
Measurable target lesion is hottest single tumor
lesion SUVlbw of ‘‘maximal 1.2-cm diameter
volume ROI in tumor” (Peak SUVlbw). Peak SUVlbw is
at least 1.5-fold greater than liver SUVlbw mean +2
SDs (in 3-cm spherical ROI in normal right lobe of
liver). If liver is abnormal, primary tumor should
have uptake > 2.0 SUVlbw mean of blood pool in 1-
cm-diameter ROI in descending thoracic aorta
extended over 2-cm z-axis.
Uptake measurements should be made for peak
and maximal single-voxel tumor SUVlbw. Other
SUV metrics, including SUVlbw mean at 50% or
70% of Peak SUV, can be collected as exploratory
data; TLG can be collected ideally on basis of
voxels more intense than 2 SDs above liver mean
SUL
RECIST, Response Evaluation Criteria in Solid Tumors, European Organization for Research and Treatment of Cancer; PERCIST,
PET Response Criteria in Solid Tumors; CT, Computed Tomography, ROI: Region of interest, SD, standard deviation.
Table 1. Evaluation of baseline lesions
Target Lesions Non-Target Lesions
CR Disappearance of all target lesions. Any pathological
lymph nodes must have reduction in short axis to <10
mm.
Disappearance of all non-target lesions and
normalization of tumor marker level. All lymph nodes
must be non-pathological in size (<10 mm short axis).
PR ≥ 30% decrease in the sum of diameters of target
lesions, taking as reference the baseline sum
diameters.
N/A
SD Neither sufficient shrinkage to qualify for PR nor
sufficient increase to qualify for PD, taking as
reference the smallest sum diameters while on study.
N/A
PD ≥ 20% increase in the sum of diameters of target
lesions, taking as reference the smallest sum on study
(including the baseline sum if that is the smallest on
study). In addition to the relative increase of 20%, the
sum must also demonstrate an absolute increase of at
least 5 mm.
The appearance of one or more new lesions is also
considered progression.
Unequivocal progression of existing non-target lesions.
The appearance of one or more new lesions is
considered progression.
Non-CR/
Non-PD
N/A Persistence of one or more non-target lesion(s) and/or
maintenance of tumor marker level above the normal
limits.
Adapted from Eisenhauer et al. (2009) [75]. CR, Complete Response; PR, Partial Response; SD, Stable Disease; PD, Progressive
Disease; N/A, Not Applicable
Table 2. RECIST 1.1 (Non-metabolic) response criteria
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Response IWC[79] IWC+PET[80]
CR - no detectable clinical or radiographic
evidence of disease
- no disease-related symptoms
- no biochemical abnormalities
- negative BMB (if positive before treatment)
- lymph nodes >1.5 cm at baseline regress to
≤ 1.5 cm
- lymph nodes 1.1-1.5 cm at baseline regress
to ≤ 1.0 cm
-CR by IWC with a completely negative PET
- CRu, PR, or SD by IWC with a completely negative PET
and negative BMB if positive prior to therapy
- PD by IWC with a completely negative PET and CT
abnormalities (new lesion or increasing size of
previous lesion) ≥ 1.5 cm (≥ 1.0 cm in the lungs) and
negative BMB if positive prior to therapy
CRu - same as CR but either residual lymph mass
> 1.5cm transverse diameter that has
regressed > 75% or indeterminate BMB
- CRu by IWC with a completely negative PET but with
an indeterminate BMB
PR - ≥ 50% reduction in SPD of the six largest
dominant nodes or nodal masses
- no increase in size of spleen, liver, or other
nodes
- no new sites of disease
- CR, CRu, or PR by IWC with a positive PET at the site
of a previously involved node/nodal mass
- CR, CRu, PR, or SD by IWC with a positive PET outside
the site of a previously involved node/nodal mass
- SD by IWC with a positive PET at the site of a
previously involved node/nodal mass that regressed to
< 1.5 cm if previously > 1.5 cm, or < 1 cm if previously
1.1-1.5 cm
SD - less than PR but not PD - SD by IWC with a positive PET at the site of a
previously involved node/nodal mass
PD - applies only to patients with PR or
nonresponders
- ≥ 50% increase in the SPD from nadir of
any previously identified abnormal node
- any new lesion
- PD by IWC with a positive PET finding corresponding
to the CT abnormality (new lesion, increasing size of
previous lesion)
- PD by IWC with a negative PET and a CT abnormality
(new lesion, increasing size of previous lesion) of < 1.5
cm (< 1.0 cm in the lungs)
RD - applies only to patients with CR or Cru
- ≥ 50% increase in size of previously
involved sites or
- ≥ 50% increase in greatest diameter of any
previously identified node > 1cm in short
axis or
- ≥ 50% increase in the SPD of ≥ 2 nodes or
- any new lesion
(not defined)
Adapted from Juweid et al. (2005) [79]. IWC, International Workshop Criteria; PET, positron emission tomography; CR,
complete remission; CRu, unconfirmed complete response, BMB, bone marrow biopsy, CT, computed tomography; PR,
Partial Response; SPD, sum of the product of the diameters; SD, stable disease; PD, progressive disease; RD, relapsed
disease
Table 3. IWC+PET-based response definitions for lymphoma based on IWC designations and PET findings
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Response Definition Nodal Masses Spleen, Liver Bone Marrow
CR Disappearance of
all evidence of
disease
(a) FDG-avid or PET positive
prior to therapy; mass of any
size permitted if PET negative
(b) Variably FDG-avid or PET
negative; regression to normal
size on CT
Not palpable,
nodules
disappeared
Infiltrate cleared on repeat
biopsy; if indeterminate by
morphology,
immunohistochemistry
PR Regression of
measurable
disease and no
new sites
≥ 50% decrease in SPD of up
to 6 largest dominant masses;
no increase in size of other
nodes
(a) FDG-avid or PET positive
prior to therapy; one or more
PET positive at previously
involved site
(b) Variably FDG-avid or PET
negative; regression on CT
≥ 50% decrease in
SPD of nodules (for
single nodule in
greatest transverse
diameter); no
increase in size of
liver or spleen
Irrelevant if positive prior to
therapy; cell type should be
specified
SD Failure to attain
CR/PR, or PD
(a) FDG-avid or PET positive
prior to therapy; PET positive
at prior sites of disease and no
new sites on CT or PET
(b) Variably FDG-avid or PET
negative; no change in size of
previous lesions on CT
Relapsed
Disease or PD
Any new lesion or
increase of
previously involved
sites by ≥ 50%
from nadir.
Appearance of a new lesion(s)
> 1.5 cm in any axis, 50%
increase in SPD of more than
one node, or > 50% increase
in longest diameter of a
previously identified node >1
cm in short axis
Lesions PET positive if FDG-
avid lymphoma or PET positive
prior to therapy.
> 50% increase
from nadir in the
SPD of any previous
lesions
New or recurrent
involvement
From Cheson et al. Revised Response Criteria for Malignant Lymphoma (2007) [78]. CR, Complete Remission; FDG, 18F-
fluorodeoxyglucose; PET, positron emission tomography; CT, computed tomography; PR = Partial Remission, SPD =
sum of the product of the diameters; SD, stable disease; PD, progressive disease.
Table 4. PET response definitions for clinical trials
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Response EORTC PERCIST 1.0 PERCIST Comment
Metabolic CR
(CMR)
Complete resolution of 18F-
FDG uptake within tumor
volume so that it was
indistinguishable from
surrounding normal tissue.
Complete resolution of 18F-FDG uptake
within measurable target lesion so that it is
less than mean liver activity and
indistinguishable from surrounding
background blood-pool levels.
No new 18F-FDG-avid lesions in pattern
typical of cancer.
Disappearance of all other lesions to
background blood-pool levels.
Percent reduction in SUVlbw should
be recorded from measurable
region and time (weeks) after
treatment initiated
(i.e., CMR 290, 4).
If anatomic progression by RECIST,
must verify with follow-up.
Metabolic PR
(PMR)
Reduction of minimum of
15% ± 25% in tumor 18F-FDG
SUV after 1 cycle of
chemotherapy, and >25%
after >1 treatment cycle.
Reduction in extent of tumor
18F-FDG uptake is not a
requirement for PR.
≥ 0.8 and ≥ 30% reduction of Peak* 18F-
FDG SUVlbw in target measurable tumor.
No new lesions.
SUVlbw measurement is obtained from the
most active lesion also present at baseline
(even if a different lesion than measured at
baseline).
No increase > 30% in SUVlbw or size of
target or nontarget lesions.
Measurement is of the single most
active lesion after treatment that
was also present at baseline (e.g.
may be a different lesion). Percent
reduction in SUVlbw should be
recorded and time in weeks after
treatment initiated
(i.e., PMR -40, 3).
If anatomic progression by RECIST,
must verify with follow-up.
Reduction in extent of tumor 18F-
FDG uptake is not requiremed.
Metabolic SD
(SMD)
Increase in tumor 18F-FDG
SUV <25% or decrease of <
15% and no visible increase
in extent of 18F-FDG tumor
uptake (20% in longest
dimension).
No CMR, PMR, or PMD. Peak SUVlbw in metabolic target
lesion should be recorded, as well
as time (weeks) from initation of
most recent therapy, in weeks
(i.e., SMD -15, 7).
Metabolic PD
(PMD)
Increase in 18F-FDG tumor
SUV of >25% within tumor
region defined on baseline
scan; visible increase in extent
of 18F-FDG tumor uptake
(20% in longest dimension)
or appearance of new 18F-
FDG uptake in metastatic
lesions.
(1) >30% and >0.8 increase in 18F-FDG
Peak* SUVlbw from baseline in pattern
typical of tumor and not of infection/
treatment effect.
Or
(2) Visible increase in extent of 18F-FDG
tumor uptake (75% in TGA volume with
no decline in SUVlbw
Or
(3) New 18F-FDG-avid lesions that are
typical of cancer and not related to
treatment effect or infection.
PD other than new visceral lesions
should be confirmed on follow-up
study within 1 month unless clearly
associated with PD by RECIST 1.1.
Should report percent change in
Peak SUVlbw, time elased since
treatment (weeks) and whether
new lesions are present/absent
and their number
(i.e., PMD, 135, 4, new: 5).
Adapted from Wahl et al.[43]. TLG, total lesion glycolysis; CMR, complete metabolic response; PMR, partial metabolic response;
PD, progressive disease; SMD, stable metabolic disease; PMD, progressive metabolic disease; CR, complete remission; PR, partial
remission.
*Single-voxel SUVlbw (e.g. “SUVmax”) is commonly used but has been reported to be less reproducible than Peak SUVlbw, especially
with very small single-voxel values. Peak SUVlbw represents the highest mean value of a 1.2-cm-diameter spherical volume with‐
in a lesion and reduces variability secondary to voxel-to-voxel noise. It is suggested, but not required, that lesions assessed on
PERCIST be larger than the 1.5-cm-diameter volume ROI used to minimize partial-volume effects.
Table 5. Metabolic Objective Response Assessment with 18F-FDG PET: EORTC & PERCIST 1.0
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4. Clinical relevance of treatment response assessment
4.1. Head & neck cancer – Definitive/preoperative chemoradiation
18F-FDG PET has found a particularly significant role in treatment of head and neck cancers.
It has long shown promise in its ability to prognosticate; in 37 patients from 1991-1994 with
head and neck squamous cell carcinomas (HNSCC) receiving baseline 18F-FDG PET, SUVmaxshowed correlation with aggressive disease and potential prediction for survival [81].
Beyond prognostication, 18F-FDG PET is now routinely used to adapt treatment management,
particularly in obviating surgical neck dissection in patients with complete response to initial
radiation or chemoradiation therapy. Early studies have supported observation and omission
of planned dissection after definitive radiotherapy for node-positive HNSCC with complete
response on CT imaging, though at least selective nodal dissection was routinely practiced for
residual neck masses [82,83]. With implementation of 18F-FDG PET, its negative predictive
value has further supported omission of planned neck dissection, including in patients with
residual neck mass/lymphadenopathy [84–88].
In an early study by Yao et al. [84], 41 patients from 2000-02 with locally-advanced HNSCC
received radiation therapy with or without chemotherapy as upfront treatment had pretreat‐
ment and follow-up CT and 18F-FDG PET, with follow-up imaging 2.5-6 months (usually 3-4
months) post-treatment. Those without residual lymphadenopathy were observed. Twelve of
41 had residual lymphadenopathy; all had pathological testing, four with fine needle aspira‐
tion (FNA) biopsy, and eight had neck dissection. Follow-up 18F-FDG PET correlated better
than follow-up CT for residual disease, and SUVmax cutoff of < 3.0 had 100% negative predictivevalue and 80% positive predictive value, serving as a good “rule-out” test for residual disease
and potential to forego planned neck dissection in favor of initial observation, thus decreasing
overall toxicity [84].
In a further analysis, Yao et al. (2005) [85] reviewed findings in 53 patients (70 heminecks; 17
patients with bilateral disease) with N2A or higher HNSCC with complete response to
radiation therapy (± chemotherapy). Forty-two had clinically positive (exam or CT) lympha‐
denopathy but negative PET; this group had option to pursue dissection; 17 were observed,
and 4 had negative neck dissection. The remaining 7 heminecks had clinically and PET-positive
lymphadenopathy, six had neck dissection, one FNA; three were positive and four were
negative for residual disease. No regional recurrences had occurred after median follow-up of
26 months (range 12-57 months). Negative predictive value of PET was 100% and positive
predictive value 43%. They conclude that observation is safe if both CT and PET-negative 12
weeks after treatment and potentially also if CT reveals small (e.g. <2-3 cm) but PET-negative
lymphadenopathy.
Porceddu et al. [88] analyzed a select cohort of 39 patients with HNSCC treated with definitive
radiotherapy (± chemotherapy) with (a) complete regression of the primary HNSCC, (b)
clinical evidence of residual neck mass by exam or CT imaging 8 weeks after treatment, (c) a
follow-up 18F-FDG PET (median 12 weeks), and (d) either pathologic confirmation of neck
status or > 12 months follow-up. Seven patients had residual PET uptake in the mass and
proceeded to neck dissection (five were positive). Of the 32 with no residual tumor uptake,
five had neck dissection (all pathologically negative), and 27 were observed (median follow-
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up of 34 months). One of the 27 observed patients had recurrence, yielding 97% negative
predictive value. They conclude that in patients with a residual neck mass that is PET-negative
12 weeks after definitive radiotherapy (± chemotherapy), neck dissection is not required, and
patients can be safely observed.
Such studies support timing of follow-up 18F-FDG PET to be 12 weeks post-treatment
[84,85,88]. High negative predictive value (91%) has been shown at 16 weeks [86] post-
treatment, though early time points (e.g. 4 weeks) have shown increased false positives [87].
Metaanalyses support PET ≥ 12 weeks after completion of definitive therapy for moderately
higher diagnostic accuracy. An added benefit of 18F-FDG PET at this early follow-up interval
is the potential to spare neck dissection in patients who show early distant metastatic disease
[88,89].
Despite lack of any randomized prospective studies, significant retrospective evidence has
continued to show similar findings. Recent metaanalyses [90–92], discuss 26, 27, and 51 studies
including up to 2335 patients [92], overall supporting the high negative predictive value
(approximately 95%) of follow-up PET and its value in omitting planned neck dissection.
Further, despite the increased costs of PET imaging, PET-guided management in patients with
complete response at the primary site has shown to be the more cost effective than CT-guided
management or planned neck dissection [93].
4.2. Rectal cancer – Preoperative chemoradiation
Similar to HNSCC, first line treatment for locally-advanced rectal cancer includes upfront
chemoradiation. In this setting, however, subsequent planned surgery remains standard of
care. This multimodality neoadjuvant approach has shown to decrease local recurrence and
improve overall survival [94,95]. Furthermore, neoadjuvant treatment has shown to increase
sphincter-preserving surgery, conferring decreased surgical morbidity and improved quality
of life [96–98].
Deferring subsequent surgical intervention in this disease site has similarly been investigated.
In a cohort of 71 patients with distal rectal carcinoma considered resectable prior to concurrent
chemoradiation with subsequent complete clinical response treated subsequently with
observation alone (no planned surgery), five-year overall and disease-free survivals were 100%
and 92%, respectively.
Improving restaging methods after neoadjuvant chemotherapy provides clinicians with
increased information to guide management. Radiographic imaging modalities, however, are
less sensitive to assessment of pathologic response, which is better characterized by metabolic
imaging with 18F-FDG PET [54,99,100].
A number of studies have attempted correlation of 18F-FDG PET with tumor downstaging and
response to neoadjuvant chemoradiation [100–105]. In a study by Capirci et al. [100] including
81 patients with locally-advanced rectal cancer, percent reduction of SUVmax from baseline to
follow-up 18F-FDG PET at 5-6 weeks after concurrent chemoradiation was most predictive of
responders (71% reduction) versus non-responders (38% reduction) based on Mandard’s
criteria. They propose a cutoff of 65% reduction, yielding 85% sensitivity, 80% specificity, 81%
positive predictive value, 84% negative predictive value, and 81% accuracy.
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Notably, surgery is routinely planned approximately 6 weeks after neoadjuvant treatment, as
surgery at 6-weeks was shown to have more tumor downstaging than at 2 weeks [106].
However, further tumor response and increased survival has been noted with intervals > 7
weeks [107]. A recent similar study by Perez et al. (2012) [105] of 91 patients with follow-up
18F-FDG PET at 6 weeks but also again at 12 weeks showed best separation of good responders
(49%) versus bad responders (51%) at 12 weeks (SUVmax of 9.1 in bad responders vs. 4.3 in good
responders, p<0.001) rather than at 6 weeks (SUVmax of 6.4 in bad responders versus 5.8 in good
responders, p=0.5). Good responders were more likely to have complete clinical response (38%
vs. 7%, p=0.001) complete or near-complete pathologic response (45% vs. 16%, p=0.008) and
smaller pathologic size (3.3 vs. 4.4, p=0.03). Increase from early-phase (1 hour after injection)
to delayed-phase PET (3 hours after injection) at the 6 –week time point was 67% accurate of
predicting good vs. bad responders. A good responder was considered anyone with
SUV12week < SUV6week. They conclude that approximately half of patients will have continued
improved response beyond 6 weeks, whereas approximately half will have increased meta‐
bolic activity. Dual-phase imaging at the 6-week point may help stratify the two groups, which
may help guide clinicians in best timing for planned surgery.
In rectal cancer, 18F-FDG PET restaging does show promise in potentially affecting treatment
management; prospective studies investigating its role in this setting are awaited.
4.3. Lymphoma
18FDG-PET finds various roles in management of lymphoma. For staging in Hodgkin lym‐
phoma (HL) and non-Hodgkin lymphoma (NHL), PET with CT (PET-CT) has been shown to
improve sensitivity and specificity in evaluation of nodal and extranodal sites in comparison
to contrast-enhanced CT without PET [108,109]. It has further shown to be 92% sensitive for
bone marrow involvement in HL [110]. Beyond staging, PET has been used for post-chemo‐
therapy restaging, assessing response during chemotherapy at initial diagnosis, and also
during salvage treatment. In current NCCN guidelines for both HL & NHL, PET-CT has
variably been incorporated into staging, restaging during chemotherapy, and restaging after
chemotherapy; routine PET-CT in the surveillance setting, however, is recommended against
secondary to false-positive risk [111,112].
Restaging
The role for PET in lymphoma is clearest in the setting of restaging, either during or subsequent
to treatment. PET has a very high negative predictive value (88-100%, see Table 6) [113].
Further, after treatment, PET is superior to CT for distinguishing residual mass with versus
without residual viable disease (e.g. post-treatment fibrosis) [114]. Spaepen et al. report on two
cohorts, one with HL [115] and one with NHL [116] who were assessed with PET at baseline
and after completion of chemotherapy. In the HL cohort [115] of 60 patients, 55 were PET- (PET
negative) after chemotherapy and 5 were PET+ (PET positive). All 5 PET+ patients had relapse
of disease. Of the PET- patients, 91% remained without recurrence after median follow-up of
32 months. Two-year PFS rates were 91% vs. 0% for PET- vs. PET+ patients (p<0.0001).
Similarly, in the NHL cohort [116] of 93 patients, all 27 PET+ patients after chemotherapy had
relapse (median 2.4 months), whereas 84% of the PET- patients remained in remission (median
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21 months). Two-year PFS rates were 85% vs. 4% for PET- vs. PET+ patients (p<0.0001). Halasz
et al. (2011) [117] report a summary of post-chemotherapy and interim PET results. They further
report a cohort of 59 patients with NHL, receiving 36 Gy (median) consolidative in-field
radiation therapy (RT) (all patients) and R-CHOP chemotherapy (58 of 59 patients). Median
follow-up was 47 months. In the 66% with negative PET after chemotherapy, 3-year PFS was
97%. However, with this treatment including RT, 3-year PFS was 90% in those with positive
PET after chemotherapy (p-value not reported).
Author Year n PPV (%) NPV (%)
HL
Spaepen [115] 2001 60 100 91%
Cerci [118] 2010 130 92% 100%
Engert [119] 2012 728 N/A 95%
NHL
Bangerter [120] 1998 89 90% 98%
Jerusalem [114] 1999 35 43% 100%
Zinzani [121] 1999 31 93% 100%
Mikhaeel [122] 2000 45 60% 100%
Naumann [123] 2001 15 86% 88%
Spaepen [116] 2001 93 70% 100%
Gigli [124] 2008 42 75% 94%
Cashen [125] 2011 50 80% 92%
Adapted from Cheson [113]. HL, Hodgkin Lymphoma; NHL, Non-Hodgkin Lymphoma; PPV, positive predictive value; NPV,
negative predictive value
Table 6. Positive and negative predictive value of PET-CT in lymphoma staging
Interim (during-chemotherapy) PET
More research has investigated interim (during chemotherapy) 18FDG-PET for assessment of
treatment response and prognostication (see Table 7). Cerci et al. [126] assessed interim PET
after 2 cycles of ABVD (coxorubicin, bleomycin, vinblastine, and dacarbazine) chemotherapy
in 104 patients with early and advanced Hodgkin lymphoma. Negativity vs. positivity at
interim PET significantly predicted event-free survival (EFS), 91% vs. 53% at 3 years for PET-
vs. PET+ patients (p<0.001). On univariate analysis, interim PET was the best prognosticator
of event-free survival (p<0.001), more so than stage, bulky disease, and international prognostic
score (IPS) (p=0.24, p=0.15, p=0.99, respectively). It however failed to prognosticate survival
(p=0.2), which was better predicted by age (cutoff 45 years, p=0.01) and IPS (0-2 vs. 3-7, p=0.04).
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Author Year n FU(months) # cycles
Interim PET
Response Outcomes p-value
HL
Hutchings [127] 2005 85 40 2-3
74% PET-
11% PET+
15% MRU
97% 2y PFS
46% 2y PFS <0.001
Hutchings [109] 2006 77 23 2 79% PET-21% PET+
96% 2y PFS
0% 2y PFS <0.001
Kostakoglu [128] 2006 23 21 1 74% PET-26% PET+
100% 2y PFS
13% 2y PFS <0.001
Zinzani [129] 2006 40 18 2 80% PET-20% PET+
97% PFS
12% PFS <0.001
Gallamini [130] 2007 260 26 2 81% PET-19% PET+
95% 2y PFS
13% 2y PFS <0.001
Markova [131] 2009 50 25 4 72% PET-28% PET+
100% PFS
28% PFS NR
Cerci [126] 2010 104 36 2 71% PET-29% PET+
91% 3y EFS
53% 3y EFS <0.001
NHL
Jerusalem [114] 2000 28 18 3 82% PET-18% PET+
62% 2y PFS
0% 2y PFS <0.001
Spaepen [132] 2002 70 36 2-3 53% PET -47% PET +
16% progressed
100% progressed <0.001
Haioun [133] 2005 90 24 2 60% PET -40% PET +
82% 2y EFS
43% 2y EFS <0.001
Mikhaell [134] 2005 121 29 2-3
41% PET -
43% PET +
16% MRU
88% 5y PFS
16% 5y PFS
59% 5y PFS
<0.001
Ng [135] 2007 45 31 1-5 69% PET -31% PET +
15% relapsed
61% relapsed <0.001
Han [136] 2009 40 24 2-4 68% PET -32% PET +
10% progressed
71% progressed NR
Pregno [137] 2009 88 26 2-4 72% PET -28% PET +
85% 2y PFS
72% 2y PFS 0.048
Safar [138] 2009 112 38 2 63% PET -37% PET +
84% 3y PFS
47% 3y PFS <0.001
Cashen [125] 2011 50 15 2-3 52% PET -48% PET +
85% 2y PFS
63% 2y EFS 0.031
Zinzani [139] 2011 91 50 variable 62% PET-39% PET+
75% 4y EFS
18% 4y EFS <0.001
HL, Hodgkin Lymphoma; NHL, Non-Hodgkin Lymphoma; PET, positron emission tomography; FU, Follow-up; n, number of pa‐
tients in study with interim PET scan; EFS, event-free survival; PFS, progression-free survival; MRU, minimal residual uptake; #
cycles, number of cycles of chemotherapy completed prior to interim PET; NR, not reported
Table 7. Prognostication of interim PET in lymphoma
Positron Emission Tomography - Recent Developments in Instrumentation, Research and Clinical Oncological Practice206
Drug salvage
In the setting of relapsing/refractory Hodgkin lymphoma, interim PET after 2 cycles of salvage
high-dose chemotherapy has been assessed. Limited retrospective data from Castagna et al.
[125] has shown similar prognostic potential, reporting 2-year progression-free survival of 93%
(PET-negative) versus 10% (PET-positive, p<0.001).
PET Response-Adapted radiotherapy
In the German Hodgkin Study Group HD15 trial (2012) [119,140] with over 2,000 patients with
advanced-stage Hodgkin lymphoma, 3 BEACOPP chemotherapy regimens were compared in
a non-inferiority randomized trial. Radiotherapy was implemented with a “PET-guided”
adaptive approach based on post-chemotherapy response regardless of treatment arm. If a
PET-positive persistent mass 2.5cm or larger was present after completion of chemotherapy
(median 21 days), 30Gy local radiation therapy was administered for consolidation. Negative
predictive value for post-chemotherapy PET was 94% at 12 months follow-up. In the 3 arms,
five-year freedom from failure ranged from 84%-89%, and five-year survival ranged from
92-95%. Consolidative radiotherapy was not randomized and was administered to 11% of
patients (compared to 71% in HD9 [141]). With such excellent outcomes with this PET-guided
radiotherapy approach, the authors indicate this approach as their current standard of care.
Longer follow-up and prospective clinical trials assessing need for consolidative radiotherapy
are still awaited.
4.4. Esophageal cancer – Definitive/preoperative
The role of multimodality therapy for esophageal and gastroesophageal cancer has historically
not been well defined. Resection has been considered standard treatment for patients with
resectable/localized disease without strong evidence supporting neoadjuvant therapy, despite
significant risk for local and distant recurrences yielding poor 5-year survival rates ranging
from 15-39%[142]. Neoadjuvant treatment is increasingly becoming adopted as standard of
care for locally-advanced disease, with use continuing to increase [143,144]. Multiple prospec‐
tive trials did not report survival benefit with neoadjuvant chemoradiotherapy [145–147], and
randomized studies supporting neoadjuvant treatment are scarce. Walsh et al. (1996) [148]
showed increased 3-year overall survival from 6% to 32% with neoadjuvant treatment (p<0.01)
in a study of 113 patients. In the recently published CROSS trial [149] with 366 patients,
addition of neoadjuvant chemoradiation increased R0 resection (resection with negative
pathologic margins) from 69% to 92% (p<0.001) and more than doubled median overall
survival from 24 to 49 months (hazard ratio = 0.66, p=0.003).
In patients receiving neoadjuvant chemoradiation, a portion—29% in the Dutch CROSS study
—are found to have pathologic complete response on subsequent surgery. In a single-
institution review, pathologic complete response from neoadjuvant treatment was associated
with higher 5-year and overall survival (48% vs. 18% and 50 months vs. 28 months, respec‐
tively) in comparison to patients without complete response [150]. With treatment response
bearing significant prognostic potential, assessment of response to neoadjuvant treatment for
esophageal cancer has been an area of increasing research [150–163].
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In an early study by Weber et al. (2001) [151] in forty patients receiving neoadjuvant chemo‐
therapy (without radiotherapy) for esophageal cancer, patients had 18FDG-PET both pretreat‐
ment and after 14 days of treatment (during chemotherapy). Metabolic response was
considered decrease of 35% from baseline, which was associated with 93% sensitivity and 95%
Figure 1. This is a 12-year-old female with a history of Stage IIB bulky nodular sclerosing Hodgkin lymphoma involving
the bilateral cervical chain and mediastinum. She had achieved a complete response with 6 cycles of COPP-ABV che‐
motherapy. She then received a total radiation dose of 3060 cGy in 17 fractions of 180 cGy to the cervical and media‐
stinal lymph nodes. As seen in the serial PET/CT images (b-f above), the mediastinal and cervical lymph nodes
responded well. However, by 28 months post-treatment, a left iliacus muscle lymph node became suspicious for lym‐
phoma involvement (g – max SUV 5.0). By 31 months post-treatment, this node had increased further (h – max SUV
7.7).
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specificity for prediction of clinical response. Responders had longer time to progression/
recurrence and overall survival.
In a follow-up study [152], patients had three 18FDG-PET scans: one pretreatment, one during
treatment (2 weeks after starting), then 3-4 weeks preoperatively (but after neoadjuvant
treatment. Responders had more decrease at 2 weeks (44% vs. 21%, p<0.01) and preoperatively
(70% vs. 51%, p=0.01). During-treatment PET had higher power than the preoperative PET
treatment to predict response (area under curve (AUC) of receiver operator characteristic
(ROC) 0.78 vs. 0.88), though difference was not statistically significant (p=0.40). Best cutoff for
response in this cohort was 30% reduction from baseline (93% sensitive, 88% accurate), who
all proceed to have R0 resection. Responders by this PET criteria had higher survival (median
38 vs. 18 months; 2-year rates 79% vs. 38%, p<0.01).
Analysis of gastroesophageal junction tumors again showed improved prognostic potential
with PET using percent reduction of SUVmax 2 weeks after treatment start (p=0.03) versus after
completion of neoadjuvant treatment (p=0.09) [153]. Though percent reduction is routinely
used to assess response, thresholds of decrease of SUVmax (e.g. decrease of ≥10) from before to
after neoadjuvant treatment have shown to predict significant histopathologic response [158].
More recent studies have showed other metrics as better predictors of response. In a compar‐
ison of SUVmax, MTV based on fixed threshold of 2.5 SUV, and SUVmean (of MTV), and TGA,
MTV and TGA were both 91% sensitive in predicting histopathologic response when also using
CT, but MTV increase specificity from 90% to 93%. Most predictive was TGA (AUC=0.95)
followed by MTV (AUC=0.92), SUVmax (AUC=0.84), and SUVmean (AUC=0.82) [159]. Further,
metabolic response criteria (e.g. PERCIST) have shown better assessed response in comparison
to non-metabolic methods (e.g. RECIST and WHO) [159,163].
With various studies showing prognostic potential of 18FDG-PET early during treatment, there
is question as to the utility of PET to potentially facilitate treatment modification [152]. Kwee
(2010) [160] performed a metaanalysis of 20 PET-response studies including 849 patients; it
however showed wide ranges of sensitivity and specificity with overall AUC of 0.78. Based on
the pooled data, PET was not recommended for routine clinical use to guide neoadjuvant
treatment. Furthermore, in a retrospective single-institution review [164], patients treated with
neoadjuvant chemotherapy followed by surgery had similar freedom from local failure
(p=0.92) and overall survival (p=0.15) in comparison to patients receiving definitive chemora‐
diation who attained metabolic CR (SUV<3). Furthermore, in this retrospective study, though
not statistically significant, rate of death in the definitive chemoradiation group was higher
than in the surgical group despite worse baseline characteristics.
Similar to head and neck cancer, prospective studies are awaited to formally assess necessity
of surgical management after complete metabolic response to neoadjuvant chemoradiation
therapy in operable/resectable patients.
4.5. Non-Small Cell Lung Cancer (NSCLC)
18FDG-PET is currently recommended by NCCN guidelines for routine staging of stage I-III
NSCLC [67]. Radiotherapy planning with PET fusion has further been recommended for
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biologically-targeted radiotherapy in which 3D-PET fusion is implemented for tumor delin‐
eation, with PET performed with minimal delay between PET and start of treatment, given
propensity for rapid disease progression [64–66,165]. Metabolic (PET) response to treatment
has been shown to pre-date radiographic (CT) response. Despite increasing data showing
utility of PET for assessing treatment response in NSCLC and predicting outcomes including
survival, guidelines currently do not recommend PET in this setting [44,45,67,76,166–177].
In an early study of 15 patients receiving chemotherapy for IIIB-IV NSCLC, patients received
weekly PET starting at initiation of chemotherapy until completion of 2 cycles (6 weeks later)
[171]. Reduction of SUVmax by 50% week 1 to week 3 was predictive of survival of > 6 months,
thus facilitating prediction of response to treatment. Those with less reduction died within 6
months. In patients without early response, management may thus be altered to forego futile
chemotherapy. In an early study [167] of 15 stage I-III patients receiving radiotherapy, patients
received 3 PETs: one pre-treatment, one during treatment after approximately 45 Gy, and one
3 months post-treatment. Response during treatment was shown to correlate with overall
response after treatment (p=0.03), and SUV during treatment correlated with SUV 3 months
after (p<0.001). A number of studies with prospective PET data with cutoffs are listed in Table 8.
Author Year n Stage Criteria Outcome p
Vansteenkiste [172] 1985 15 IIIA 50% decrease OS 0.03
MacManus [173] 2003 73 I-III CMR OS <0.01
Weber [174] 2003 57 IIIB-IV 20% decrease OS <0.01
Hellwig [175] 2004 47 IIB-III SUV < 4 OS <0.01
Eschmann [176] 2007 70 III CMR or 80% decrease OS <0.01
de Geus-Oei [177] 2007 51 IB-IV 35% decrease OS 0.02
Nahmias [171] 2007 16 IIIB-IV 50% decrease from week 1 toweek 3 OS <0.01
Tanvetyanon [178] 2008 89 IB-IIIB CMR OS NS
At 12 months
Mangona [45] 2012 129 IA-IB
SUV ≥ 3.9
60% decrease
SUV ≥ 6.0
LF* <0.01
LF* <0.01
LF† <0.01
During treatment
Mangona [70] 2012 16 IIB-IIIB 30% decreasedecrease ≥ 4
CSS <0.01
LRR <0.01
Adapted from Hicks et al. [170]. CMR, complete metabolic response; OS, overall survival; LF, local failure; CSS, cause-
specific survival; LRR, locoregional recurrence; NS, not statistically significant.*100% sensitive. †100% specific.
Table 8. PET Cutoffs/Criteria and Outcomes in NSCLC
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SBRT
Stereotactic body radiotherapy (SBRT), employing modern techniques including 4-D treat‐
ment planning and image-guided radiotherapy (IGRT) has been shown to be an effective, cost-
efficient, treatment option for definitive management of early-stage NSCLC as well as lung
metastases from other organs with excellent tumor control rates; in comparison to medically-
operable patients who are treated with resection, retrospective data of primarily medically-
inoperable patients with poor pulmonary function suggests excellent tumor control with SBRT
with rates similar to that of sublobar resection and minimal toxicity [179–191].
In a large single-institution analysis [45] of 129 consecutive NSCLC tumors treated with SBRT,
58% enrolled on a prospective phase II protocol, patients had baseline and serial follow-up
PET imaging. Sixteen patients additionally had weekly on-treatment 4D-PET-CT. Median
follow-up was 19 months and median time until local failure (LF) of 15 months. A total of 475
PETs were obtained. Change in SUV from pre-treatment to follow-up are seen in Figure 1 and
stratified by status of LF vs. no-LF based on last follow-up. Though baseline SUVmax was higher
in the LF group (12.4 vs. 6.5, p=0.0001), difference was not significant at 1.5 and 6 months, as
both groups responded. SUV at 12 months, however, was significantly higher for the LF vs.
no-LF group (6.8 vs. 2.5, p=0.02). Cutoffs predictive of LF were 12-month SUV ≥ 3.9 (100
sensitive), 12-month SUV ≥ 6 (100 specific), and 12-month SUV ≥ 40% of baseline (see Table
8). Analysis of SUVmax velocity showed trend for higher velocity at 12 months (+0.18 SUV/
month vs. -0.03 SUV/month, p=0.058). On multivariate logistic regression, 12-month SUV was
most predictive of LF (p=0.057).
Hyperfractionated radiotherapy
In a cohort of 16 patients with locally-advanced NSCLC enrolled on a phase II protocol, patients
had PET at baseline, weekly during treatment, and at follow-up [70,192] (see Figure 2). Patients
received hyperfractionated radiation therapy 1.5 Gy BID with concurrent chemotherapy either
as definitive treatment (n=12) or as neoadjuvant treatment (n=4) delivering RT with daily
online cone-beam CT for image guidance and intensity modulated radiotherapy (IMRT) to
minimize potential normal tissue toxicity [190,193,194]. After potential follow-up of 20 months
(range 12-28), 7 had locoregional recurrence (LRR), and 8 died (5 of disease). Interestingly,
there was trend for higher SUVmax at baseline in those without LRR (the no-LRR group) than
in those with LRR (19.0 vs. 11.9, p=0.08), an inverse relationship than expected. The rate of SUV
decrease in the LRR group during RT was 1.6 per week, significantly faster than the no-LRR
group (0.23 per week, p=0.02) such that SUV values were similar for both groups by the 4th on-
treatment PET (p=0.95) (see Table 9). A during-RT decrease of less than 4 from baseline was
predictive of LRR (p<0.01), and a during-RT decrease less 30% from baseline was predictive
of death from disease (p<0.01). Velocity of retention index from PET1 to PET-FU predicted
overall survival (+1.6%/week in those who died vs. -1.7%/week in those alive, p=0.03).
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Assessment of response for NSCLC with serial 18FDG-PET. 129 node-negative non-small-cell lung tumors were treated
with stereotactic body radiation therapy (SBRT) and followed with routine follow-up imaging. SUV for tumors with
eventual local failure (LF) and no local failure (no-LF) at last follow-up are compared. (a) Plot of SUVmax vs. time, with
baseline PET SUVmax at t=0. Tumors with resulting LF show higher SUVmax both at pre-treatment and at 12-months fol‐
low-up, though SUVmax at 1.5 and 6 months were similar. (b) Plot of normalized SUVmax (baseline normalized SUV = 1).
Normalized SUVmax is higher at 12 months in the LF group but similar at other time points. Values are plotted as box
plots with thick black line representing the median value, lower box border the 25th percentile, upper box border the
75th percentile, and outliers with points. PET SUVs subsequent to any treatment for recurrence (e.g. chemotherapy)
were excluded; thus, the no-LF group had data at longer follow-up (e.g. 24, 36, and 48 months).
Figure 2. SUV kinetics after stereotactic body radiotherapy for NSCLC
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PET0 PET1 PET2 PET3 PET4 PET-FU Velocity duringRT
SUVmax
LRR 11.9 9.5 11.4 10.6 9.8 6.7 -0.23/week
no-LRR 19.0 17.3 16.3 12.8 9.4 4.6 -1.60/week
p 0.08 0.02 0.13 0.32 0.95 0.66 0.02
SUVdelayed-
SUVearly
LRR 1.90 2.00 2.15 1.30 0.95 -0.05/week
no-LRR - 4.20 2.80 1.60 1.55 0.61 -0.68/week
p 0.02 0.15 0.82 0.55 0.82 0.15
Retention Index
LRR 23.3% 22.5% 22.8% 14.3% 18.4% -0.8%/week
no-LRR - 27.1% 19.8% 18.5% 15.3% 17.6% -3.4%/week
p 0.92 0.88 0.16 0.57 0.76 0.04
Patients had PET-CT before treatment for staging/planning (PET0), weekly during treatment (PET1, PET2, PET3, and PET4),
and at 6-12 weeks follow-up (PET-FU); RT, Radiation Therapy; LRR, locoregional recurrence; no-LRR, no locoregional
recurrence at last follow-up.
Table 9. On-treatment SUV kinetics of locally-advanced NSCLC treated with concurrent chemoradiation
PET shows prognostic potential in this disease site from prior to treatment to early in treatment,
to later in follow-up. It further holds potential for adjusting management (e.g. discontinuing
ineffective chemotherapy, potentially modifying radiation therapy during treatment, and
predicting delayed local failure for potential earlier biopsy/intervention). We await further
prospective PET data and clinical trials to best define the role of PET in assessment of treatment
in NSCLC.
5. Future directions
As PET is used for staging and radiotherapy prior to treatment for a number of organ sites,
PET further has potential for restaging and replanning radiotherapy during the course of
therapy. Beyond mid-treatment prognostication, this facilitates potential treatment modifica‐
tion. For radiotherapy re-planning, potential changes are include modification of target
volumes based on anatomic changes from treatment, modification of boost volumes, and
potentially adjustment of prescription dose based on response (e.g. higher dose for poor
responders vs. less dose for good responders). Such investigations are currently ongoing in
clinical protocols.
In treatment of locally-advanced head and neck squamous cell carcinomas, our institution has
initiated a prospective, non-randomized trial evaluating the utility of such an adaptive
approach focusing on target volume adaptation. Patients receiving 70 Gy IMRT in 35 daily
fractions (7 week duration) with concurrent cisplatin or cetuximab are eligible. 18FDG-PET-CT
is utilized for treatment planning. Repeat PET-CTs and diagnostic CTs are obtained after
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fractions 10 and 22 for the purpose of treatment adaptation. Three different treatment plans
will be created, one for fractions 1-12 (based on pre-treatment PET-CT), one for fractions 13-24
(based on PET-CT after fraction 10), and one for fractions 25-35 (based on PET-CT after fraction
22). Such an adaptive approach may help decrease dose delivered to normal tissue as tumors
decrease in size during treatment, potentially decreasing toxicity. On this protocol, patients
also obtain weekly PET-CTs for assessment of treatment response, though prescription dose
is not modified in this study.
For non-small cell lung cancer, investigators have further used on-treatment PET to facilitate
PET-adaptive replanning, with PET-adaptive dose escalation incorporated into a currently-
enrolling Radition Therapy Oncology Group (RTOG) Protocol, RTOG 1106 [195,196]. All
1.5 Gy twice daily with concurrent Taxotere. He had a complete metabolic response to treatment evident at first fol‐
low-up PET 1-month after treatment. SUV values (early → delayed): (a) Pre: 29.4 → 36.9; (b) Week 1: 17.8 → 23.6; (c)
Week 2: 13.3 → 16.0; (d) Week 3: 15.7 → 17.0; (e) Week 4: 4.6 → 5.8; (f) Week 5: 4.2 → 5.3; (g) 1 month follow-up: 2.0 →
2.2
Figure 3. This is a 68-year-old male who presented with dyspnea and hemoptysis. Workup revealed a stage IIIB (T4,
N2, M0) squamous cell carcinoma of the right lower lobe, 7cm in size invading the mediastinum. He received hyper‐
fractionated intensity-modulated radiotherapy, 66 Gy in 1.5 Gy fractions twice daily.
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patients on this protocol will have 18FDG-PET; however, a subset are planned to also have 18F-
MISO-PET at staging.
As such radiotracers beyond 18F-FDG show particular promise, further results of clinical trials
implementing these are awaited.
6. Conclusion
Over the past 20 years, the body of data assessing treatment response with PET has grown
significant. Assessing treatment response with PET can yield highly prognostic information.
Such information, however, may have no end-effect on management. As clinicians, many of
our PET-based decisions are based on retrospective and prospective data without comparison
of management options based on PET results. Such results are significantly hypothesis-
generating. The high negative predictive value of PET in various organ sites may increase
comfort of clinicians when considering omitting potentially unnecessary interventions (e.g.
neck dissection after complete metabolic response of locally-advanced head and neck cancer
SUV values (early → delayed): (a) Pre: 23.4 → 28.7; (b) Week 1: 14.8 → 16.0; (c) Week 2: 11.0 → 12.7; (d) Week 3: 11.0 →
12.8; (e) Week 4: 12.1 → 15.; (f) 6-week FU: 6.5 → 8.; (g) 6-month FU: 12.5 → 15.7; (h) 8-month FU: 4.9 → 6.3
Figure 4. This is a 66-year-old male who presented with right shoulder pain. Workup revealed a clinical stage IIIA (T3
N1 M0) squamous cell carcinoma of the right upper lobe of the lobe with chest wall invasion causing destruction of
ribs 2-4. He received hyperfractionated intensity-modulated radiotherapy 72Gy, 1.5 Gy twice daily, with concurrent
and maintenance taxotere for 4 months. SUV nadir occurred at 6 weeks with evident local progression at 6 months.
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to chemoradiation, esophagectomy after complete metabolic response to chemoradiotion, or
consolidative radiotherapy after complete metabolic response in Hodgkin lymphoma). High-
level evidence to justify such treatment-adapting decisions based on PET are currently lacking,
thus we caution application of such data as justification for modifying standard of care. We
strongly encourage PET-adaptive management under the guise of clinical trials at this time,
as the role of PET in oncology continues to best be defined.
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